Bionor Readies Key Trial To Prove 'Shock And Kill' Could Lead To Functional HIV Cure

Bionor Pharma ASA has met the primary endpoint of its REDUC HIV 'shock and kill' trial, which tested a potential vaccine to cure HIV/AIDS.